1. Zouboulis C.C., Nogueira da Costa A., Makrantonaki E. et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020; 34 (4): 846 - 861.

2. Goldburg S.R., Strober B.E., Payette M.J. Part I. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2020; 82 (5): 1045 - 1058.

3. Frew J.W. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence. JAAD Int. 2020; 1: 62 - 72.

4. Danby F.W., Jemec G.B., Marsch W.C., von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol. 2013; 168 (5): 1034 - 1039.

5. Vossen A.R., van der Zee H.H., Prens E.P. Hidradenitis suppurativa: A systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018; 9: 2965.

6. Sabat R., Jemec G.B., Matusiak L. et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020; 6 (1): 18.

7. Kamp S., Fiehn A.M., Stenderup K. et al. Hidradenitis suppurativa: a disease 571 of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol. 2011; 164 (5): 1017 - 1022.

8. Naik H.B., Nassif A., Ramesh M.S. et al. Are bacteria infectious pathogens in hidradenitis suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017. J Invest Dermatol. 2019; 139 (1): 13 - 16.

9. Jenei A., Dajnoki Z., Medgyesi B. et al. Apocrine gland-rich skin has a non-inflammatory IL-17-related immune milieu, that turns to inflammatory IL-17-mediated disease in hidradenitis suppurativa. J Invest Dermatol. 2019; 139 (4): 964 - 968.

10. Nikolakis G., Join-Lambert O., Karagiannidis I. et al. Bacteriology of hidradenitis suppurativa/acne inversa: A review. J Am Acad Dermatol. 2015; 73 (5 Suppl 1): S12 - 18.

11. Ring H.C., Thorsen J., Saunte D.M. et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol. 2017; 153 (9): 897 - 905.

12. Guet-Revillet H., Jais J.P., Ungeheuer M.N. et al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa: A prospective metagenomic study. Clin Infect Dis. 2017; 65 (2): 282 - 291.

13. Ring H.C., Riis Mikkelsen P., Miller I.M. et al. The bacteriology of hidradenitis suppurativa: a systematic review. Exp Dermatol. 2015; 24 (10): 727 - 731.

14. Jahns A.C., Killasli H., Nosek D. et al. Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients. APMIS. 2014; 122 (9): 804 - 809.

15. Matusiak , Bieniek A., Szepietowski J.C. Bacteriology of hidradenitis suppurativa - which antibiotics are the treatment of choice? Acta Derm Venereol. 2014; 94 (6): 699 - 702.

16. Kathju S., Lasko L.A., Stoodley P. Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol Med Microbiol. 2012; 65 (2): 385 - 389.

17. Ring H.C., Bay L., Nilsson M. et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol. 2017; 176 (4): 993 - 1000.

18. Ring H.C., Bay L., Kallenbach K. et al. Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa. Acta Derm Venereol. 2017; 97 (2): 208 - 213.

19. van der Zee H.H., de Ruiter L., van den Broecke D.G. et al. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol. 2011; 164 (6): 1292 - 1298.

20. Witte-Handel E., Wolk K., Tsaousi A. et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019; 139 (6): 1294 - 1305.

21. Kelly G., Hughes R., McGarry T. et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015; 173 (6): 1431 - 1439.

22. Shah A., Alhusayen R., Amini-Nik S. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res. 2017; 66 (11): 931 - 945.

23. Smith M.K., Nicholson C.L., Parks-Miller A., Hamzavi I.H. Hidradenitis suppurativa: an update on connecting the tracts. F1000Research. 2017; 6: 1272.

24. Frew J.W., Hawkes J.E., Krueger J.G. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Research. 2018; 7: 1930.

25. Moran B., Sweeney C.M., Hughes R. et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17: Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol. 2017; 137 (11): 2389 - 2395.

26. Jimenez-Gallo D., de la Varga-Martinez R., Ossorio-Garcia L. et al. Effects of adalimumab on T-helper-17 lymphocyte-and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Cytokine. 2018; 103: 20 - 24.

27. Matusiak , J., Bieniek A. et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017; 76 (4): 670 - 675.

28. Родионов А.Н., Скрек С.В., Соболев А.В. и др. Гнойный гидраденит. Часть I. Вестник дерматологии и венерологии. 2017; (5): 47 - 51.

29. Albanesi C., Cavani A., Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol. 1999; 162 (1): 494 - 502.

30. Fossiez F., Djossou O., Chomarat P. et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996; 183 (6): 2593 - 2603.

31. Hotz C., Boniotto M., Guguin A. et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016; 136 (9): 1768 - 1780.

32. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004; 75 (2): 163 - 189.

33. Mozeika E., Pilmane M., Nurnberg B.M., Jemec G.B. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm Venereol. 2013; 93 (3): 301 - 304.

34. Byrd A.S., Carmona-Rivera C., O'Neil L.J. et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa. Sci Transl Med. 2019; 11 (508): eaav5908.

35. Kidacki M., Cong Z., Flamm A. et al. Invasive proliferative gelatinous mass of hidradenitis suppurativa contains distinct inflammatory components. Br J Dermatol. 2019; 181 (1): 192 - 193.

36. Frew J.W., Navrazhina K., Marohn M. et al. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/acne inversa. Exp Dermatol. 2019; 28 (8): 886 - 891.

37. Riis P.T., Ring H.C., Themstrup L., Jemec G.B. The role of androgens and estrogens in hidradenitis suppurativa - A systematic review. Acta Dermatovenerol Croat. 2016; 24 (4): 239 - 249.

38. Karagiannidis I., Nikolakis G., Zouboulis C.C. Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin. 2016; 34 (1): 45 - 49.

39. Gauntner T.D. Hormonal, stem cell and Notch signalling as possible mechanisms of disease in hidradenitis suppurativa: a systems-level transcriptomic analysis. Br J Dermatol. 2019; 180 (1): 203 - 204.

40. Ingram J.R. The genetics of hidradenitis suppurativa. Dermatol Clin. 2016; 34 (1): 23 - 28.

41. Wang B., Yang W., Wen W. et al. Gamma-secretase gene mutations in familial acne inversa. Science. 2010; 330: 1065.

42. Pink A.E., Simpson M.A., Desai N. et al. Mutations in the -secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012; 132 (10): 2459 - 2461.

43. Frew J.W., Vekic D.A., Woods J., Cains G.D. A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa. Br J Dermatol. 2017; 177 (4): 987 - 998.

44. Giamarellos-Bourboulis E.J., Platzer M., Karagiannidis I. et al. High copy numbers of -defensin cluster on 8p23.1, confer genetic susceptibility, and modulate the physical course of hidradenitis suppurativa/acne inversa. J Invest Dermatol. 2016; 136 (8): 1592 - 1598.

45. Savva A., Kanni T., Damoraki G. et al. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. Br J Dermatol. 2013; 168 (2): 311 - 317.

46. Hana A., Booken D., Henrich C. et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci. 2007; 80 (24-25): 2214 - 2220.

47. Garg A, Papagermanos V, Midura M, Strunk A. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol. 2018; 178 (3): 709 - 714.

48. Kurzen H., Kurokawa I., Jemec G.B. et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008; 17 (5): 455 - 472.

49. Radek K.A., Elias P.M., Taupenot L. et al. Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. Cell Host Microbe. 2010; 7 (4): 277 - 289.

50. Wu Y., Ma Y., Xu T. et al. Nicotine enhances Staphylococcus epidermidis biofilm formation by altering the bacterial autolysis, extracellular DNA releasing, and polysaccharide intercellular adhesion production. Front Microbiol. 2018; 9: 2575.

51. Balgobind A., Finelt N., Strunk A., Garg A. Association between obesity and hidradenitis suppurativa among children and adolescents: a population-based analysis in the United States. J Am Acad Dermatol. 2020; 82 (2): 502 - 504.

52. Garg A., Lavian J., Lin G. et al. Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017; 77 (1): 118 - 122.

53. Ingram J.R., Jenkins-Jones S., Knipe D.W. et al. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018; 178; 917 - 924.

54. Deckers I.E., van der Zee H.H., Boer J., Prens E.P. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol. 2015; 72 (3): 485 - 488.

55. Vazquez B.G., Alikhan A., Weaver A.L. et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013; 133 (1): 97 - 103.

56. Zouboulis C.C., Desai N., Emtestam L. et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015; 29 (4): 619 - 644.

57. Calao M., Wilson J.L., Spelman L. et al. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. PloS One. 2018; 13 (7): e0200683.

58. Garg A., Kirby J.S., Lavian J. et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017; 153 (8): 760 - 764.

59. Fimmel S., Zouboulis C.C. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010; 2 (1): 9 - 16.

60. Sabat R., Chanwangpong A., Schneider-Burrus S. et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012; 7 (2): e31810.

61. Tzellos T., Zouboulis C.C., Gulliver W. et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015; 173 (5): 1142 - 1155.

62. Principi M., Cassano N., Contaldo A. et al. Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. World J Gastroenterol. 2016; 22 (20): 4802 - 4811.

63. Ramos-Rodriguez A.J., Timerman D., Khan A. et al. The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014. Int J Dermatol. 2018; 57 (5): 547 - 552.

64. Dauden E., Lazaro P., Aguilar M.D. et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018; 32 (1): 129 - 144.

65. Richette P., Molto A., Viguier M. et al. Hidradenitis suppurativa associated with spondyloarthritis - results from a multicenter national prospective study. J Rheumatol. 2014; 41 (3): 490 - 494.

66. Miller I.M., Ellervik C, Vinding G.R. et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014; 150 (12): 1273 - 1280.

67. Menter A. Recognizing and managing comorbidities and complications in hidradenitis suppurativa. Semin Cutan Med Surg. 2014; 33 (3 Suppl): S54 - 56.

68. Theut Riis P., Saunte D.M., Benhadou F. et al. Low and high body mass index in hidradenitis suppurativa patients-different subtypes? J Eur Acad Dermatol Venereol. 2018; 32 (2): 307 - 312.

69. Bui T.L., Silva-Hirschberg C., Torres J., Armstrong A.W. Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol. 2018; 78 (2): 395 - 402.

70. Wertenteil S., Strunk A., Garg A. Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa. J Am Acad Dermatol. 2019; 80 (5): 1308 - 1313.

71. Wertenteil S., Strunk A., Garg A. Incidence of obstructive sleep apnoea in patients with hidradenitis suppurativa: a retrospective population-based cohort analysis. Br J Dermatol. 2018; 179 (6): 1398 - 1399.

72. Deckers I.E., Benhadou F., Koldijk M.J. et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol. 2017; 76 (1): 49 - 53.

73. Hsiao J.L., Antaya R.J., Berger T. et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010; 146 (11): 1265 - 1270.

74. Miller I.M., McAndrew R.J., Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016; 34 (1): 7 - 16.

75. Yadav S., Singh S., Edakkanambeth Varayil J. et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016; 14 (1): 65 - 70.

76. Kridin K., Shani M., Schonmann Y. et al. Psoriasis and hidradenitis suppurativa: A large-scale population-based study. J Am Acad Dermatol. 2018 Nov 28: S0190-9622(18)32962-1.

77. Tiri H., Jokelainen J., Timonen M. et al. Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents. J Am Acad Dermatol. 2018; 79 (3): 514 - 519.

78. Delany E., Gormley G., Hughes R. et al. A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venereol. 2018; 32 (3): 467 - 473.

79. Thorlacius L., Cohen A.D., Gislason G.H. et al. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018; 138 (1): 52 - 57.

80. Tiri H., Huilaja L., Jokelainen J. et al. Women with hidradenitis suppurativa have an elevated risk of suicide. J Invest Dermatol. 2018; 138 (12): 2672 - 2674.

81. Chapman S., Delgadillo D., Barber C., Khachemoune A. Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication. Acta Dermatovenerologica Alpina Pannonica Adriat. 2018; 27 (1): 25 - 28.

82. Nielsen V.W., A.R., Thomsen S.F. Fatal outcome of malignant transformation of hidradenitis suppurativa: A case report and literature review. Clin Case Rep. 2020; 8 (3): 504 - 507.

83. Lavogiez C., Delaporte E., Darras-Vercambre S. et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010; 220 (2): 147 - 153.

84. Pena Z.G., Sivamani R.K., Konia T.H., Eisen D.B. Squamous cell carcinoma in the setting of chronic hidradenitis suppurativa; report of a patient and update of the literature. Dermatol Online J. 2015; 21 (4): 13030/qt9q9707dp.

85. Micheletti R. Tobacco smoking and hidradenitis suppurativa: associated disease 526 and an important modifiable risk factor. Br J Dermatol. 2018; 178 (3): 587 - 588.

86. Garg A., Papagermanos V., Midura M. et al. Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: A population-based analysis in the United States. J Am Acad Dermatol. 2018; 79 (3): 495 - 500.e1.

87. Theut Riis P., Thorlacius L., Knudsen List E., Jemec G.B. A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark. Br J Dermatol. 2017; 176, 1083 - 1085.

88. Matusiak L., Bieniek A., Szepietowski J.C. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J. Am. Acad. Dermatol. 2010; 62; 706 - 708.

89. Kromann C.B., Deckers I.E., Esmann S. et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014; 171 (4): 819 - 824.

90. Egeberg A., Gislason G.H., Hansen P.R. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatology. 2016; 152 (4): 429 - 434.

91. Canoui-Poitrine F., Revuz J.E., Wolkenstein P. et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009; 61 (1): 51 - 57.

92. Poli F., Wolkenstein P., Revuz J. Back and face involvement in hidradenitis suppurativa. Dermatology. 2010; 221 (2): 137 - 141.

93. Kim W.B., Sibbald R.G., Hu H. et al. Clinical features and patient outcomes of hidradenitis suppurativa: A cross-sectional retrospective study. J Cutan Med Surg. 2016; 20 (1): 52 - 57.

94. Zouboulis C.C., Del Marmol V., Mrowietz U. et al. Hidradenitis suppurativa/Acne inversa: Criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015; 231 (2): 184 - 190.

95. Zouboulis C.C., Bechara F.G., Fritz K. et al. S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa* (ICD-10 Ziffer: L73.2). J Dtsch Dermatol Ges. 2012; 10 Suppl 5: S1 - 31.

96. Rompel R., Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg. 2000; 26 (7): 638 - 643.

97. Saunte D.M.. Jemec G.B. Hidradenitis suppurativa: Advances in diagnosis and treatment. JAMA. 2017; 318 (20): 2019 - 2032.

98. Boer J. Should hidradenitis suppurativa be included in dermatoses showing Koebnerization? Is it friction or fiction? Dermatology. 2017; 233: 47 - 52.

99. Kamal N., Cohen B.L., Buche S. et al. Features of patients with Crohn's disease and hidradenitis suppurativa. Clin Gastroenterol Hepatol. 2016; 14 (1): 71 - 79.

100. Hessam S., Scholl L., Sand M. et al. Distinguishing mild, moderate, and severe hidradenitis suppurativa. JAMA Dermatol. 2018; 154 (3): 330 - 335.

101. Родионов А.Н., Соболев А.В., Скрек С.В. и др. Гнойный гидраденит. Часть II. Вестник дерматологии и венерологии. 2017; (6): 41 - 46.

102. Brown T.J., Rosen T., Orengo I.F. Hidradenitis suppurativa. South Med J. 1998; 91 (12): 1107 - 1114.

103. Parulkar I., Haleem H., Paek S.Y. Epidemiologic and clinical features of hidradenitis suppurativa. Semin Cutan Med Surg. 2017; 36 (2): 42 - 46.

104. Shalom G. Hidradenitis suppurativa: epidemiology, clinical features, associated comorbidities and treatment. G Ital Dermatol Venereol. 2017; 152 (1): 46 - 57.

105. Alikhan A., Lynch P.J., Eisen D. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol. 2009; 60 (4): 539 - 561.

106. Matusiak , J., Kaaz K. et al. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018; 98 (2): 191 - 194.

107. Patel Z.S., Hoffman L.K., Buse D.C. et al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017; 21 (12): 49.

108. Kouris A., Platsidaki E., Christodoulou C. et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016; 232 (6): 687 - 691.

109. Hurley H.J. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Dermatologic Surgery: Principles and Practice (Roenigk R.K., Roenigk H.H., eds). New York: Marcel Dekker, 1989; 729 - 739.

110. Napolitano M., Megna M., Timoshchuk E.A. et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017; 10: 105 - 115.

111. Kimball A.B., Kerdel F., Adams D. et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012; 157 (12): 846 - 855.

112. Amano M., Grant A., Kerdel F.A. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010; 49 (8): 950 - 955.

113. Grant A., Gonzalez T., Montgomery M.O. et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo controlled crossover trial. J Am Acad Dermatol. 2010; 62 (2): 205 - 217.

114. Sartorius K., Emtestam L., Jemec G.B., Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009; 161 (4): 831 - 839.

115. Micheletti R.G. Natural history, presentation, and diagnosis of hidradenitis suppurativa. Semin Cutan Med Surg. 2014; 33 (3 Suppl): S51 - 53.

116. Saunte D.M., Boer J., Stratigos A. et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015; 173 (6): 1546 - 1549.

117. Vekic D.A., Frew J., Cains G.D. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. Australas J Dermatol. 2018; 59 (4): 267 - 277.

118. Pilkington T., Brogden R.N. Acitretin. A review of its pharmacology and therapeutic use. Drugs. 1992; 43 (4): 597 - 627.

119. Ortiz N.E., Nijhawan R.I., Weinberg J.M. Acitretin. Dermatol Ther 2013; 26 (5): 390 - 399.

120. Hanson N., Leachman S. Safety issues in isotretinoin therapy. Semin Cutan Med Surg. 2001; 20: 166 - 183.

121. Ellis C.N., Krach K.J. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001; 45 (5): 150 - 157.

122. Ertam I., Alper S., Unal I. Is it necessary to have routine blood tests in patients treated with isotretinoin? J Dermatolog Treat. 2006; 17 (4): 214 - 216.

123. D., de la R., L. et al. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm. 2017; 2017: 2450401.

124. Wolverton S.E. Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol. 1992; 26: 661 - 679.

125. Molinelli E., Paolinelli M., Campanati A. et al. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol. 2019; 15 (5): 367 - 379.

126. Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010; 63 (6): 949 - 972.

127. Bessissow T., Renard M., Hoffman I. et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012; 36 (4): 312 - 323.

128. Zhu Y.I., Stiller M.J. Dapsone and sulphones in dermatology: Overview and update. J Am Acad Dermatol. 2001; 45: 420 - 434.

129. Rossi R.E., Parisi I., Despott E.J. et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol. 2014; 20 (46): 17352 - 17359.

130. Kok B., Lester E.L., Lee W.M. et al. Acute liver failure from tumor necrosis factor- antagonists: Report of four cases and literature review. Dig Dis Sci. 2018; 63 (6): 1654 - 1666.

131. Shah P., Sundaram V., E. Biologic and checkpoint inhibitor-induced liver injury: A systematic literature review. Hepatol Commun. 2020; 4 (2): 172 - 184.

132. French J.B., Bonacini M., Ghabril M. et al. Hepatotoxicity associated with the use of anti-TNF- agents. Drug Saf. 2016; 39 (3): 199 - 208.

133. Ghabril M., Bonkovsky H.L., Kum C. et al. Liver injury from tumor necrosis factor- antagonists: Analysis of thirty-four cases. Clin Gastoenterol Hepatol. 2013; 11 (5): 558 - 564.e3.

134. E.S., Gunnarsson B.I., G. et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastoenterol Hepatol. 2015; 13 (3): 602 - 608.

135. M.J., Torre-Cisneros J., B. et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011; 137 (12): 533 - 540.

136. Burmester G.R., Gordon K.B., Rosenbaum J.T. et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: An updated analysis. Adv Ther. 2020; 37 (1): 364 - 380.

137. Wortsman X., Jemec G.B. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg. 2007; 33 (11): 1340 - 1342.

138. Wortsman X., Moreno C., Soto R. et al. Ultrasound in- depth characterization and staging of hidradenitis suppurativa. Dermatol. Surg. 2013; 39 (12): 1835 - 1842.

139. Wortsman X., Castro A., Figueroa A. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016; 75 (4): 760 - 767.

140. Kelly A.M., Cronin P. MRI features of hidradenitis suppurativa and review of the literature. AJR Am J Roentgenol. 2005; 185 (5): 1201 - 1204.

141. Griffin N., Williams A.B., Anderson S. et al. Hidradenitis suppurativa: MRI features in anogenital disease. Dis Colon Rectum. 2014; 57 (6): 762 - 771.

142. Virgilio E., Bocchetti T., Balducci G. Utility of MRI in the diagnosis and post-treatment evaluation of anogenital hidradenitis suppurativa. Dermatol. Surg. 2015; 41 (7): 865 - 866.

143. Хобейш М.М., Шустов Д.В., Соколовский Е.В. Гидраденит суппуративный: современные представления о патогенезе, терапии и успешный опыт лечения адалимумабом. Вестник дерматологии и венерологии. 2017; (5): 70 - 81.

144. von Laffert M., Helmbold P., Wohlrab J. et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010; 19: 533 - 537.

145. Yu C.C., Cook M.G. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990; 122 (6): 763 - 769.

146. Gulliver W., Zouboulis C.C., Prens E. et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016; 17 (3): 343 - 351.

147. Goldburg S.R., Strober B.E., Payette M.J. Hidradenitis suppurativa: Current and emerging treatments. J Am Acad Dermatol. 2020; 82 (5): 1061 - 1082.

148. Lalvani A., Millington K.A. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev. 2008; 8 (2): 147 - 152.

149. Godfrey M.S., Friedman L.N. Tuberculosis and biologic therapies: Anti-tumor necrosis factor- and beyond. Clin Chest Med. 2019; 40 (4): 721 - 739.

150. Frew J.W., Hawkes J.E., Krueger J.G. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019 Mar 1; 10: 2040622319830646.

151. Alikhan A., Sayed C., Alavi A. et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019; 81 (1): 91 - 101.

152. Масюкова С.А., Мордовцева В.В., Землякова С.А. и др. Hydradenitis suppurativa: Лечение. Часть 3. Российский журнал кожных и венерических болезней. 2016; 19 (4): 233 - 237.

153. Danesh M.J., Kimball A.B. Pyrithione zinc as a general management strategy for hidradenitis suppurativa. J Am Acad Dermatol. 2015; 73 (5): e175.

154. Clemmensen O.J. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983; 22: 325 - 328.

155. Jemec G.B., Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998; 39 (6): 971 - 974.

156. Vekic D.A., Cains G.D. Hidradenitis suppurativa - management, comorbidities and monitoring. Aust Fam Physician. 2017; 46 (8): 584 - 588.

157. Hogan D.J., Light M.J. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol. 1988; 19 (2 Pt 1): 355 - 356.

158. Boer J., Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011; 164 (1): 170 - 175.

159. Matusiak L., Bieniek A., Szepietowski J.C. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014; 171 (1): 170 - 174.

160. Boer J., van Gemert M.J. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999; 40 (1): 73 - 76.

161. Brown C.F., Gallup D.G., Brown V.M. Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol. 1988; 158 (1): 12 - 15.

162. Dicken C.H., Powell S.T., Spear K.L. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1984; 11 (3): 500 - 502.

163. Kaur M.R., Lewis H.M. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat. 2006; 17 (4): 211 - 213.

164. Yazdanyar S., Boer J., Ingvarsson G. et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011; 222 (4): 342 - 346.

165. Bianchi L., Hansel K., Stingeni L. Recalcitrant severe hidradenitits suppurativa successfully treated with cyclosporine A. J Am Acad Dermtol. 2012; 67 (6): e278 - 279.

166. Andreson M.D., Zauli S., Bettoli V. et al. Cyclosporine treatment of severe hidradenitis suppurativa: a case series. J Dermatol Treat. 2016; 27 (3): 247 - 250.

167. Buckley D.A., Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995; 88 (5): 289P - 290P.

168. Rose R.F., Goodfield M.J., Clark S.M. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol 2006; 31 (1): 154 - 155.

169. Kimball A.B., Okun M.M., Williams D.A. et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016; 375 (5): 422 - 434.

170. Jemec G.B., Okun M.M., Forman S.B. et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019; 181 (5): 967 - 975.

171. Lim S.Y., Oon H.H. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics. 2019 May 13; 13: 53 - 78.

172. Zouboulis C.C., Okun M.M., Prens E.P. et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2018; 80 (1): 60 - 69.

173. van der Zee H.H., Longcore M., Geng Z., Garg A. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2020; 34 (5): 1050 - 1056.

174. Mekkes J.R., Bos J.D. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008; 158 (2): 370 - 374.

175. Paradela S., Rodriguez-Lojo R., Fernandez-Torres R. et al. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat. 2012; 23 (4): 278 - 283.

176. van Rappard D.C., Leenarts M.F., Meijerink- van't Oost L. et al. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2012; 23 (4): 284 - 289.

177. Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol 2016; 75 (5): 1059 - 1062.

178. Finley E.M., Ratz J.L. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol. 1996; 34 (3): 465 - 469.

179. Lapins J., Marcusson J.A., Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br J Dermatol. 1994; 131 (4): 551 - 556.

180. Lapins J., Sartorius K., Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol. 2002; 47 (2): 280 - 285.

181. Hazen P.G., Hazen B.P. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010; 36 (2): 208 - 213.

182. Madan V., Hindle E., Hussain W. et al. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol. 2008; 159 (6): 1309 - 1314.

183. van Rappard D.C., Mooij J.E., Mekkes J.R. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol. 2012; 26 (7): 898 - 902.

184. Shaughnessy D.M., Greminger R.R., Margolis I.B. et al. Hidradenitis suppurativa. A plea for early operative treatment. JAMA. 1972; 222: 320 - 321.

185. Banerjee A.K. Surgical treatment of hidradenitis suppurativa. Br J Surg. 1992; 79 (9): 863 - 866.

186. Mandal A., Watson J. Experience with different treatment modules in hidradenitis suppuritiva: a study of 106 cases. Surgeon. 2005; 3 (1): 23 - 26.

187. Bieniek A., Matusiak L., Chlebicka I. et al. Secondary intention healing in skin surgery: our own experience and expanded indications in hidradenitis suppurativa, rhinophyma and non-melanoma skin cancers. J Eur Acad Dermatol Venereol. 2013; 27 (8): 1015 - 1021.

188. Bieniek A, Matusiak L, Okulewicz-Gojlik D., Szepietowski J.C. Surgical treatment of hidradenitis suppurativa: experiences and recommendations. Dermatol Surg. 2010; 36 (12): 1998 - 2004.

189. Humphries L.S., Kueberuwa E., Beederman M., Gottlieb L.J. Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: A single-center experience. J Plast Reconstr Aesthet Surg. 2016; 69 (4): 554 - 566.

190. Bohn J., Svensson H. Surgical treatment of hidradenitis suppurativa. Scand J Plast Reconstr Surg Hand Surg. 2001; 35 (3): 305 - 309.

191. Calibre C., Bouhanna A., Salmin J.P. et al. Axillary hidradenitis suppurativa: A single-stage surgical treatment. Ann Chir Plast Esthet. 2013; 58 (6): 670 - 675.

192. Alharbi Z., Kauczok J., Pallua N. A review of wide surgical excision of hidradenitis suppurativa. BMC Dermatol. 2012; 12: 9.

193. Busnardo F.F., Coltro P.S., Olivan M.V. et al. The thoracodorsal artery perforator flap in the treatment of axillary hidradenitis suppurativa: effect on preservation of arm abduction. Plast Reconstr Surg. 2011; 128 (4): 949 - 953.

194. Morteza Seyed Jafari S., Hunger R.E., Schlapbach C. Hidradenitis suppurativa: Current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med. (Lausanne). 2020 Mar 4; 7: 68.

195. Scheinfeld N. Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine. Dermatol Online J. 2013; 19 (11): 20616.

196. Kurzen H, Kurzen M. Secondary prevention of hidradenitis suppurativa. Dermatol Reports. 2019; 11 (2): 8243.

197. Danby F.W. Diet in the prevention of hidradenitis suppurativa (acne inversa). J Am Acad Dermatol 2015; 73 (5 Suppl. 1): S52 - 54.

198. Sivanand A., Gulliver W.P., Josan C.K. et al. Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2019; 24 (1): 64 - 72.

199. Riis P.T., Boer J., Prens E.P. et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. J Am Acad Dermatol. 2016; 75 (6): 1151 - 1155.

200. van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009; 219(2): 143 - 147.

201. Gener G., Canoui-Poitrine F., Revuz J.E. et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009; 219 (2): 148 - 154.

202. Bettoli V., Zauli S., Borghi A. et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J. Eur. Acad. Dermatol. Venereol. 2014; 28 (1): 125 - 126.

203. Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2017; 76 (2): 309 - 313.e2.

204. Bettoli V., Manfredini M., Massoli L. et al. Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol. 2019; 33 (5): 930 - 936.

205. Zouboulis C.C., Bechara F.G., Dickinson-Blok J.L. et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019; 33 (1): 19 - 31.

206. Join-Lambert O., Coignard-Biehler H., Jais J.P. et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016; 71 (2): 513 - 520.

207. Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther. 2005; 3 (1): 23 - 39.

208. Alavi A., Lynde C., Alhusayen R. et al. Approach to the management of patients with hidradenitis suppurativa: A consensus document. J Cutan Med Surg. 2017; 21 (6): 513 - 524.

209. Ingram J.R., Collier F., Brown D. et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019; 180 (5): 1009 - 1017.

210. R.F., Rivitti-Machado M.C., Duarte G.V. et al. Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology. An Bras Dermatol. 2019; 94 (2 Suppl 1): 7 - 19.

211. Hunger R.E., Laffitte E., S. et al. Swiss practice recommendations for the management of hidradenitis suppurativa/Acne inversa. Dermatology. 2017; 233 (2-3): 113 - 119.

212. Gulliver W, Landells ID, Morgan D, Pirzada S. Hidradenitis suppurativa: A novel model of care and an integrative strategy to adopt an orphan disease. J Cutan Med Surg. 2018; 22 (1): 71 - 77.

213. Sachdeva M, Kim P, Mufti A, Maliyar K, Sibbald C, Alavi A. Biologic use in pediatric patients with hidradenitis suppurativa: A systematic review. J Cutan Med Surg. 2022; 26 (2): 176 - 180.

214. Rundle CW, Price KN, Hogeling M, Hsiao JL, Shi VY. Recent advances in hidradenitis suppurativa in pediatrics. Dermatol Online J. 2020 Dec 15; 26(12): 13030/qt5gt6m9n3.

215. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf Доступно 15 июля 2025 г.

216. Prussick L., Rothstein B., Joshipura D. et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019; 181 (3): 609 - 611.

217. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023 Mar 4; 401(10378): 747 - 761.

218. Casseres R.G., Prussick L., Zancanaro P. et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. J Am Acad Dermatol. 2020; 82 (6): 1524 - 1526.

219. Ribero S., Ramondetta A., Fabbrocini G. et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021; 35 (7): e441 - e442.

220. Melgosa Ramos F.J., Ruiz R., Corrales A., Mateu Puchades A. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. 2023; 37 (4): e517 - e519.

221. D'Onghia M., Malvaso D., Galluccio G. et al. Evidence on hidradenitis suppurativa as an autoinflammatory skin disease. J Clin Med. 2024 Sep 2; 13 (17): 5211.

222. Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol. 2023 Mar 23; 14: 1124628.